2nd Quarter - Report

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$106,568
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 20, 2010 $106,568 Replaced
2nd Quarter - Report (this page) Nov 8, 2011 $106,568 Replaced
2nd Quarter - Amendment Nov 8, 2011 $106,568 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Small Business SMB

H.R. 3763 and S. 3416, amends the Fair Credit Reporting Act to provide for an exclusion from red Flag Guidelines for certain businesses; H.R. 5141 and S. 3578, Small Business Paperwork Mandate Elimination Act-amends the Internal Revenue Service Code to repeal a provision (added by the Patient Protection and Affordable Care Act) that extends to corporations that are not tax exempt the requirement to report payments of $600 or more; H.R. 4173 and S. 3217, the Wall Street Reform and Consumer Protect Act of 2009; submitted comments to Senate Committee on Homeland Security and Government Affairs supporting a cost savings proposal by the U.S. Postal Commission to decrease mail delivery from 6 days to 5 days.

LobbyistCovered position, as disclosed
ANNE CASSITY —
JOHN M COSTER —
ADNAN JALIL —

Contacted: Federal Trade Commission (FTC); Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Small Business Administration (SBA); SENATE; Treasury, Dept of; Drug Enforcement Administration (DEA); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO)

Bills named: S. 3217 (111th), S. 3578 (111th), H.R. 4173 (111th), H.R. 5141 (111th), S. 3416 (111th), H.R. 3763 (111th)

Pharmacy PHA

H.R. 1204, the Community Pharmacy Fairness Act of 2009 and S. 2191, the Community Pharmacy Fairness Act from the 110th Congress; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; H.R. 6331 (110th Congress), the Medicare Improvement for Patients and Providers Act of 2008-Sec. 172 related to the implementation of the Medciare Part D prompt pay requirements and submission of claims by pharmacies located in or contracting with long-term care facilities; H.R. 5235, the Medicare Access to Diabetic Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010-advocated for inclusion of the extension of the Federal Medicaid Matching Rate (FMAP) and limiting access to 340b drugs in outpatient settings to only eligible individuals in both House bill and Senate amendment; H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions related to pedigree and track and trace requirements-no bill introduced in the current Congress; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act , includes funding for the Department of Defense FY11 budget and covers the TRICARE pharmacy program; H.R. 3108 and S. 3543, the Medication Therapy Management Expanded Benefit Act; H.R. 2923, the Combat Meth Act of 2009; S. 1383, the Dextromethorphan Abuse Reduction Act of 2009; submitted comments to Senate Committee on Aging on prescription drug disposal and the role of nurses as agents in long-term care facilities; sought Congressional support to stop exclusion of certain retail pharmacies from "employee prescription drug plans;" worked with Congressional offices to request the FTC review the 180 day generic drug marketing exclusivity policies of certain generic manufacturers; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); submitted comments to Senate Judiciary Committee regarding the FTC and DOJ antitrust oversight; submitted comments to Senate Homeland Security and Government Affairs Committee regarding a HHS OIG report, "Invalid Prescriber Identifiers on Medicare Part D Drug Claims;" FSA debit card program-seeking Congressional support to amend IRS guidance (no legislation).

LobbyistCovered position, as disclosed
ANNE CASSITY —
JOHN M COSTER —
ADNAN JALIL —
SUSAN JANECZKO —
TONY S LEE —

Contacted: Defense, Dept of (DOD); Treasury, Dept of; HOUSE OF REPRESENTATIVES; Small Business Administration (SBA); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); SENATE

Bills named: H.R. 5234 (111th), S. 3543 (111th), H.R. 6331 (111th), S. 2191 (111th), H.R. 3790 (111th), S. 1383 (111th), H.R. 4213 (111th), H.R. 4489 (111th), H.R. 2923 (111th), H.R. 1204 (111th), H.R. 5136 (111th), H.R. 3108 (111th), S. 3454 (111th), H.R. 5839 (111th), H.R. 5235 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.